Company profile
IDEXX Laboratories, Inc.
NASDAQ: IDXX · Healthcare · Medical - Diagnostics & Research
#67 of 1,418 Healthcare companies by revenue56th-percentile growth
EA Score
88AFH 90DQ 94GM 68SS 96
v0.1 · 65/100 weight · provisional
↑ Piotroski F, return on equity · ↓ 3-yr revenue growth, balance-sheet leverage
Methodology →Revenue TTM
$4.4B
Rev growth YoY (TTM)
+13.1%
Net income (FY)
$1.1B
Employees
11,000
as of 2026-08-04
Market cap
$44.8B
as of 2026-08-04
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.3B$4.3B2025
Net income$1.1B$1.1B2025
Operating income$1.4B$1.4B2025
Total assets$3.4B$3.4B2025
Liabilities$1.7B$1.7B2025
Equity$1.6B$1.6B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product59%
Service41%
By geography
UNITED STATES61%
EMEA21%
Asia Pacific8%
Europe, the Middle East, and Africa, Other5%
CANADA4%
Latin America2%
The read
What is IDEXX Laboratories, Inc.’s revenue?
IDEXX Laboratories, Inc. booked $4.3B in FY2025 revenue, growing 10% year over year — about the middle of the pack among Healthcare companies we track, at a 24.6% net margin.
Peers · Healthcare
Elanco Animal Health Incorporated66BDexCom, Inc.87AIllumina, Inc.84B+The Cooper Companies, Inc.86AAlign Technology, Inc.83B+Mettler-Toledo International Inc.80B+Neighbors
Cumberland →Key facts
CEOMichael Erickson
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersWestbrook, ME
ExchangeNASDAQ: IDXX
Employees11,000
IPO date1991-06-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.